Look­ing to top­ple Pfiz­er's Pre­vnar 13 dy­nasty, Mer­ck claims an­oth­er win for its 'break­through' pneu­mo­coc­cal con­ju­gate vac­cine

Three months af­ter win­ning the FDA’s break­through ther­a­py des­ig­na­tion for its big­ger/bet­ter pneu­mo­coc­cal con­ju­gate vac­cine can­di­date aimed at top­pling Pfiz­er’s Pre­vnar 13 megablock­buster best­seller, Mer­ck is back with a batch of up­beat Phase II da­ta from their big clin­i­cal pro­gram.

In a nut­shell, Mer­ck re­searchers say that V114 proved non-in­fe­ri­or to Pre­vnar 13 on the line­up of pneu­mo­coc­cus strains it guards against — while al­so il­lus­trat­ing its ef­fec­tive­ness to boot up an im­mune re­sponse against two ad­di­tion­al dis­ease-caus­ing serotypes, 22F and 33F, not cov­ered by the Pfiz­er vac­cine.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN